Inhibrx Biosciences, Inc. (INBX)

NASDAQ: INBX · Real-Time Price · USD

72.27

+0.47 (0.65%)

At close: Jan 16, 2026, 4:00 PM EST

71.45

-0.82 (-1.13%)

After-hours: Jan 16, 2026, 7:55 PM EST

Inhibrx Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-155.09	1,688	-241.36	-115.33
Depreciation & Amortization	2.61	2.29	1.19	1.23
Other Amortization	1.8	2.07	4.9	-
Loss (Gain) From Sale of Assets	0	0.01	0	0.02
Loss (Gain) on Equity Investments	-	-	1.63	-
Stock-Based Compensation	11.38	58.52	24.85	17.79
Other Operating Activities	1.8	-1,997	0.13	1.62
Change in Accounts Receivable	0.73	0.38	-0.54	0.13
Change in Accounts Payable	-5.59	17.9	2.11	-0.38
Change in Unearned Revenue	-	-	-0.17	-1.1
Change in Other Net Operating Assets	-1.03	33.77	13.94	5.21
Operating Cash Flow	-143.39	-194.41	-193.31	-90.81
Capital Expenditures	-0.05	-2.6	-4.59	-0.69
Investing Cash Flow	-0.04	-2.6	-4.59	-0.69
Issuance of Common Stock	0.35	71.68	202.32	-
Other Financing Activities	-0.13	-	-0.36	91.5
Financing Cash Flow	100.19	71.68	201.96	91.5
Net Cash Flow	-43.24	-125.33	4.06	-
Free Cash Flow	-143.44	-197.01	-197.9	-91.5
Free Cash Flow Margin	-10245.64%	-98503.00%	-10994.56%	-6957.95%
Free Cash Flow Per Share	-9.27	-13.15	-16.80	-2.12
Cash Interest Paid	6.39	11.51	26.72	-
Cash Income Tax Paid	0	0	0	0
Levered Free Cash Flow	-117.6	-118.26	-106.38	-
Unlevered Free Cash Flow	-113.76	-111.89	-91.38	-
Change in Working Capital	-5.9	52.05	15.35	3.86

Updated Nov 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q